These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7924274)

  • 1. Updates of bioequivalence programs (including statistical power approximated by Student's t).
    Wijnand HP
    Comput Methods Programs Biomed; 1994 Apr; 42(4):275-81. PubMed ID: 7924274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on: Updates of bioequivalence programs (including statistical power approximated by Student's t).
    Hauschke D
    Comput Methods Programs Biomed; 1995 Jun; 47(1):93-4. PubMed ID: 7554866
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioequivalence revisited: non-parametric analysis of two-period cross-over studies.
    Wijnand HP
    Comput Methods Programs Biomed; 1993 Aug; 40(4):249-59. PubMed ID: 8261772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gastric emptying and entero-hepatic circulation on bioequivalence assessment of ranitidine.
    Chrenova J; Durisova M; Mircioiu C; Dedik L
    Methods Find Exp Clin Pharmacol; 2010; 32(6):413-9. PubMed ID: 20852750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A note on sample size determination for bioequivalence studies with high-order crossover designs.
    Chen KW; Chow SC; Li G
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):753-65. PubMed ID: 9697082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of parametric and nonparametric two one-sided tests procedures for assessing bioequivalence of average bioavailability.
    Liu JP; Weng CS
    J Biopharm Stat; 1993 Mar; 3(1):85-102. PubMed ID: 8485538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exact calculation of power and sample size in bioequivalence studies using two one-sided tests.
    Shen M; Russek-Cohen E; Slud EV
    Pharm Stat; 2015; 14(2):95-101. PubMed ID: 25477145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bias of two one-sided tests procedures in assessment of bioequivalence.
    Liu JP; Weng CS
    Stat Med; 1995 Apr; 14(8):853-61. PubMed ID: 7644864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Power of the two one-sided tests procedure in bioequivalence.
    Phillips KF
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):137-44. PubMed ID: 2348380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust and bootstrap testing procedures for bioequivalence.
    Shen CF; Iglewicz B
    J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of student's t- or Wilcoxon-based confidence intervals for assessment of average bioequivalence.
    Hauck WW; Hauschke D; Diletti E; Bois FY; Steinijans VW; Anderson S
    J Biopharm Stat; 1997 Mar; 7(1):179-89. PubMed ID: 9056597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical aspects of bioequivalence--a review.
    Pidgen AW
    Xenobiotica; 1992 Jul; 22(7):881-93. PubMed ID: 1455906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.